Crystalline Salt Forms for Pharmaceutical Stability

The patent transforms the compound from an amorphous free base form to a crystalline salt form by changing the chemical parameters (protonation with acid). This parameter change resolves the contradiction by providing both the required stability of crystalline structures and the manufacturability through standard salt formation procedures. The crystalline salt forms exhibit enhanced stability and resistance to degradation while remaining feasible to produce through conventional pharmaceutical manufacturing methods.

The patent creates composite structures by forming salt complexes between the compound and acid counterions (such as hydrochloride, tosylate, mesylate). These composite salt forms combine the active compound with stabilizing acid components, achieving both the desired stability and ease of manufacture. The crystalline lattice structure of these composite salts provides robustness against degradation while maintaining manufacturability.

The patent segments the synthesis process into two distinct stages: first synthesizing the compound of Formula I according to existing literature methods, then separately performing salt formation with various acids. This segmentation simplifies the overall complexity by breaking down the complex crystalline salt synthesis into manageable steps, where the first stage produces the core compound and the second stage generates multiple stable salt forms through simple acid-base reactions.

The patent performs preliminary synthesis of the compound of Formula I using established procedures from prior art before undertaking salt formation. This preliminary action allows the core compound to be prepared once, after which multiple stable crystalline salt forms can be generated through straightforward acid treatment, thereby reducing overall process complexity while achieving robust final products with extended shelf life.